Loading
HKSEHealthcareBiotechnology
Latest quote
HK$3.30
−HK$0.30 · -8.33%
Wuhan YZY Biopharma Co., Ltd. is a biotechnology enterprise specializing in the development of bispecific antibody-based treatments. Its therapeutic focus areas include various cancers, their associated complications, and age-related ophthalmic conditions. The company's extensive portfolio of drug candidates aims to address a wide range of diseases, such as malignant ascites, malignant pleural effusion, various solid tumors (including pancreatic cancer, hepatocellular carcinoma, other advanced solid tumors, and HER2-positive solid tumors), small cell lung cancer, and relapsed/refractory multiple myeloma. Additionally, they are advancing therapies for COVID-19 and several eye disorders like wet age-related macular degeneration (wAMD), diabetic macular edema (DME), and other conditions characterized by abnormal blood vessel formation in the eye. The company, established in 2010, is headquartered in Wuhan, China.
Latest quote
HK$3.30
−HK$0.30 · -8.33%
Wuhan YZY Biopharma Co., Ltd. is a biotechnology enterprise specializing in the development of bispecific antibody-based treatments. Its therapeutic focus areas include various cancers, their associated complications, and age-related ophthalmic conditions. The company's extensive portfolio of drug candidates aims to address a wide range of diseases, such as malignant ascites, malignant pleural effusion, various solid tumors (including pancreatic cancer, hepatocellular carcinoma, other advanced solid tumors, and HER2-positive solid tumors), small cell lung cancer, and relapsed/refractory multiple myeloma. Additionally, they are advancing therapies for COVID-19 and several eye disorders like wet age-related macular degeneration (wAMD), diabetic macular edema (DME), and other conditions characterized by abnormal blood vessel formation in the eye. The company, established in 2010, is headquartered in Wuhan, China.
Day range
Current HK$3.30
52-week range
Current HK$3.30
Historical prices · Market data may be delayed.
Wuhan YZY Biopharma Co., Ltd. is a biotechnology enterprise specializing in the development of bispecific antibody-based treatments. Its therapeutic focus areas include various cancers, their associated complications, and age-related ophthalmic conditions. The company's extensive portfolio of drug candidates aims to address a wide range of diseases, such as malignant ascites, malignant pleural effusion, various solid tumors (including pancreatic cancer, hepatocellular carcinoma, other advanced solid tumors, and HER2-positive solid tumors), small cell lung cancer, and relapsed/refractory multiple myeloma. Additionally, they are advancing therapies for COVID-19 and several eye disorders like wet age-related macular degeneration (wAMD), diabetic macular edema (DME), and other conditions characterized by abnormal blood vessel formation in the eye. The company, established in 2010, is headquartered in Wuhan, China.
Day range
Current HK$3.30
52-week range
Current HK$3.30
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (CNY) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 65.13M CNY | 107.81M CNY | 11.92M CNY | 2.26M CNY | 12.18M CNY |
| Cost of goods sold | 58.95M CNY | 22.74M CNY | — | — | — |
| Gross profit | 6.17M CNY | 85.07M CNY | 11.92M CNY | 2.26M CNY | 12.18M CNY |
| Research and development | 73.24M CNY | 164.99M CNY | 154.47M CNY | 157.33M CNY | 112.89M CNY |
| Selling, general, and administrative | 20.87M CNY | 14.9M CNY | 22.23M CNY | 20.53M CNY | 31.5M CNY |
| Operating expenses | 94.11M CNY | 183.07M CNY | 177.37M CNY | 177.85M CNY | 144.39M CNY |
| Interest income | 739.36K CNY | 2.57M CNY | 1.34M CNY | 283K CNY | 162K CNY |
| Interest expense | 4.82M CNY | 4.08M CNY | 2.39M CNY | 2.47M CNY | 14.97M CNY |
| Depreciation and amortization | 4.28M CNY | 6.57M CNY | 6.39M CNY | 6.34M CNY | 7.03M CNY |
| Operating income | −87.93M CNY | −98M CNY | −177.37M CNY | −175.58M CNY | −132.23M CNY |
| Net income | −82.54M CNY | −97.6M CNY | −190.98M CNY | −188.87M CNY | −148.52M CNY |
Company facts updated Sep 8, 2026.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
